SEPN

Septerna, Inc. (SEPN) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers Septerna, Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2026. Septerna is a clinical-stage biotechnology company utilizing its proprietary Native Complex Platform to develop oral small molecule therapies targeting G protein-coupled receptors (GPCRs). The company is currently advancing programs in endocrinology, immunology, inflammation, and metabolic diseases. As of the filing date, the company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Liquidity: The company reported cash, cash equivalents, and marketable securities of $516.5 million as of June 30, 2026. Management believes this is sufficient to fund operations through at least 2029.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased significantly from $0.1 million in Q2 2025 to $26.7 million in Q2 2026. This is primarily driven by the Novo Collaboration Agreement (effective July 2025), which includes a $195 million upfront payment recognized over time and milestone achievements.
• Improved Net Loss: Net loss narrowed by approximately 48% on a year-over-year basis for the quarter (from $24.8M to $13.0M) and by 53% year-to-date (from $46.3M to $21.7M), largely due to the revenue recognition from the Novo deal.
• Expense Growth: Operating expenses increased by 50% year-over-year for the quarter ($29.1M to $43.6M). Research and Development (R&D) expenses rose to $35.1 million, driven by the advancement of the SEP-479 program into Phase 1 clinical trials and the initiation of partnered metabolic programs.
• Financing Activity: The company raised $13.8 million in net proceeds through its At-The-Market (ATM) equity offering program during the six months ended June 30, 2026.

Guidance, Outlook, and Risks

• Clinical Progress:
  • SEP-479 (PTH1R Agonist): First participants dosed in Phase 1 clinical trial in April 2026. Data expected in Q1 2027.
  • SEP-631 (MRGPRX2 NAM): The company is re-evaluating development strategies for mast cell-driven diseases, shifting from a planned Phase 2b trial in chronic spontaneous urticaria to capital-efficient signal-finding trials.
• Novo Collaboration: In July 2026, Septerna completed performance obligations for the first R&D Program under the Novo agreement and provided the first development candidate. Novo exercised its right to commence a new R&D Program.
• Key Risks:
  • BIOSECURE Act: Potential restrictions on using services from Chinese biotechnology companies of concern (specifically WuXi AppTec, added to the DoD 1260H list in June 2026) could impact supply chains and federal funding eligibility.
  • Development Uncertainty: As a clinical-stage company, Septerna has no approved products and faces significant risks regarding clinical trial outcomes, regulatory approvals, and the ability to raise future capital.
  • Geopolitical Factors: Ongoing conflicts and trade tensions may impact supply chains and capital markets.

Investor Verification Checklist

• Novo Revenue Recognition: Verify the specific timeline and criteria for recognizing the remaining deferred revenue ($140.4 million) from the Novo Collaboration Agreement.
• BIOSECURE Act Impact: Assess the specific operational contingency plans regarding WuXi AppTec and other China-based suppliers following the June 2026 DoD listing.
• SEP-631 Strategy: Confirm the details of the new "capital-efficient" clinical trial strategy for SEP-631 and the associated cost implications.
• Cash Burn Rate: Monitor the quarterly cash burn rate to validate the management's assertion that current liquidity ($516.5M) is sufficient through 2029.
• SEP-479 Data: Await Q1 2027 data readout for the Phase 1 trial of SEP-479 to assess safety and pharmacokinetic profiles.